Close Menu

BioCollections Worldwide Chikungunya Virus Assay

Jan 07, 2015

BioCollections Worldwide said today that it is now offering a laboratory-developed test for the detection of Chikungunya virus. The assay follows the US Centers for Disease Control and Prevention's real-time RT-PCR protocol for detection of Chikungunya virus, and detects cases in the acute stage of infection in about five hours, BCW said. The Miami-based company is providing the test through its CLIA-certified testing laboratory.

More Like This

Jul 31, 2020

Myriad Genetics Amplify for Fetal Cell-Free DNA Sequencing

Myriad Genetics has launched Amplify, which sequences the fetal cell-free DNA fragments circulating in a mother's blood and increases the fetal fraction in a sample for non-invasive prenatal screening. The company is hoping that the technology will improve the performance of its Prequel NIPS test. The analytical validation of Amplify involved samples from more than 1,000 women and showed that the fetal fraction was 2.3 times greater on average compared to standard NIPS. The improvement reduces false positive and false negative results, including for common aneuploidies, expanded aneuploidies, microdeletions, and a baby's sex, Myriad noted. The company also said that the technology will reduce the number of sampels that fail to produce a result due to low fetal fraction and deliver results to 99.9 percent of patients. 

Jul 30, 2020

Diagenode, Alithea Genomics Mercurius Bulk RNA Sequencing Services

Diagenode, a firm providing epigenomics services and library prep products, has announced a new bulk 3' mRNA sequencing service, developed in collaboration with Alithea Genomics.

The service incorporates Alithea's Mercurius barcoding for high-throughput transcriptomics and can be scaled for large study cohorts.

Jul 29, 2020

HTG Molecular Diagnostics HTG EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics has launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel, which the firm said is designed to provide molecular characteriation of aggressive, indolent, and rare lymphomas. The research-use-only panel enables investigators to measure the expression of about 300 genes linked to the lymphoma transcriptome. The panel is available in kit form or as a service at HTG's VERI/O laboratory. 

Jul 28, 2020

Twist Bioscience RUO SARS-CoV-2 Antibody Panels

Twist Bioscience is offering two new SARS-CoV-2 antibody panels for research use only.

The Twist anti-SARS-CoV-2 S1 antibody panel includes 32s human antibodies that bind with picomolar to nanomolar affinity to the S1 spike protein of the virus that causes COVID-19. The Human anti-ACE2 panel includes 48 antibodies that bind to the extracellular domain of the ACE2 receptor on human cells, the protein that facilitates entry of the coronavirus into cells.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1, or IgG2 antibodies. Individual antibodies within the panel can be licensed for further therapeutic or diagnostic development.

Jul 22, 2020

Twist Bioscience Synthetic Controls for Respiratory Viruses

Twist Bioscience has added 16 new synthetic controls for common respiratory viruses with symptoms similar to COVID-19, including influenza H1N1, influenza H32N, influenza B, rhinovirus, enterovirus, and several human coronaviruses including a prevalent mutated strain of SARS-CoV-2 (D614G.)

Applications for the products include environmental testing, assay development and verification, and diagnostic test validation.

Twist's controls are designed based on specific viral variants, cover the full viral genomes and are sequence-verified. Controls for alternative viral variants are available as custom products. The firm said RNA synthetic controls should be delivered within two weeks of ordering.

Jul 20, 2020

Bio-Techne miRNAscope Assay

Bio-Techne announced the expansion of its RNAscope platform in the form of the miRNAscope Assay. The miRNAscope Assay extends the firm's RNAscope technology to enable the in situ detection of short nucleic acid targets between 17 and 50 nucleotides, which includes microRNAs and short synthetic oligonucleotide therapeutics such as small interfering RNAs and antisense oligonucleotides.

Jul 17, 2020

Cepheid Xpert MTB/XDR

Cepheid has launched an assay to detect extensively drug-resistant tuberculosis. The CE-IVD marked Xpert MTB/XDR test uses new 10-color technology and runs on recalibrated GeneXpert instruments. It can be used to rapidly detect resistance to isoniazid, ethionamide, fluoroquinolones, amikacin, kanamycin, and capreomycin directly from patient specimens.

Jul 17, 2020

BioMérieux BioFire Mycoplasma

BioMérieux has launched BioFire Mycoplasma, an assay to detect mycoplasma bacteria in pharmaceutical products. The test is now available in the US, and will be launched in some countries in Europe and the Asia-Pacific region in the coming months.

Jul 16, 2020

RareCyte Orion Instrument

RareCyte has launched a new spatial biology analysis platform called Orion. The system is based on a patented and proprietary microscopy technology that allows comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment at what the company claims are much faster speeds and with more efficiency than existing technologies.

The platform includes the Orion instrument and associated TissuePlex reagents. The instrument images an entire pathology slide at high speed and high resolution in 21 fluorescence channels. Companion TissuePlex panels are shipped as customizable catalog labelling kits. Customers can also access the technology through RareCyte laboratory services and other specified programs.

Jul 15, 2020

Congenica Automation

Congenica has updated its clinical decision support platform by launching the Automated Classification of Known Variants product, Congenica Automation. This will provide automated classification as well as evidence and reporting of recurrent 'known' variants that customers observe in their rare disease cases. The new product aims to reduce interpretation and reporting time by 90 percent compared to the company's existing solution, so complex genomic data can be reported in as little as 5 minutes. For example, interpretation and reporting of 4,000 cases with recurrent pathogenic or likely pathogenic variants could be completed in 5 to 8 minutes for each case. Users of the new product can also create their own customized curated variant list to be used for the automated process.

Jul 14, 2020

10x Genomics Chromium Single Cell Immune Profiling v2

10x Genomics has launched the Chromium Single Cell Immune Profiling v2 product. It extends the capabilities of the original version, offering up to 60 percent increased gene detection sensitivity. The product can be used to characterize adaptive and innate immune cell diversity; identify and characterize rare cell types and biomarkers; analyze tissue microenvironment, disease progression, and drug immune response; perform large-scale antibody and TCR discovery for novel antigens; characterize immune responses to infection by measuring clonal expansions and immune cell phenotypes; and study genes and pathways with predesigned gene expression panels.

Jul 13, 2020

New England Biolabs RUO SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit

New England Biolabs has launched a real-time loop-mediated isothermal amplifcation-based (RT-LAMP) assay kit to detect SARS-CoV-2. The research-use-only kit, called the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, enables visual amplification detection using a simple heat source, with results in 30 minutes. The kit includes the firm's WarmStart Colorimetric LAMP 2X Master Mix with uracil-DNA glycosylase, a primer mix targeting the N and E regions of the SARS-CoV-2 genome, an internal control primer set and positive control template, as well as guanidine hydrochloride to increase the speed and sensitivity of the RT-LAMP reaction.

Jul 10, 2020

Bionano Genomics Bionano Prep SP Tissue and Tumor Kit

Bionano Genomics has launched the Bionano Prep SP Tissue and Tumor Kit, a DNA isolation kit for the analysis of tumors and tissues with the company's Saphyr system. The kit is designed to simplify the isolation of ultra-high molecular weight DNA from a variety of solid tumors and tissue types. DNA can be extracted in less than six hours from as little as 5 mg of fresh or frozen tissue. It was validated in bladder, lung, liver, kidney, colon, breast, prostate, brain, thyroid, ovary, testes, and uterus tissue.

Jul 08, 2020

Sema4 Signal

Sema4 has introduced Sema4 Signal, a line of bioinformatics tools and exome-based somatic and hereditary cancer genomic tests to support precision oncology care. The initial release, Sema4 Signal Hereditary Cancer, features a 112-gene panel and 16 subpanels, supported by customizable video education, analytics services, workflow tools, and genetic counseling. 

Jul 08, 2020

NIST SARS-CoV-2 Research-Grade Test Material

The National Institute of Standards and Technology has developed a reference material to aid in the evaluation and development of RT-qPCR assays for SARS-CoV-2. The reference material consists of two synthetic RNA fragments from the SARS-CoV-2 genome in a background of 5 ng/μL human Jurkat RNA (stored at –80° C, BSL-1). Fragment 1, which has a total length of 3,985 nucleotides, and includes SARS-CoV-2 sequence 25949-29698 of isolate USA-WA1/2020; and Fragment 2, which has a total length of 3,790 nucleotides and includes SARS-CoV-2 sequence 12409-15962 of isolate USA-WA1/2020.

NIST said the synthetic fragments can be used to assess limits of detection for SARS-CoV-2 assays or calibrate other in-house or commercial SARS-CoV-2 controls. NIST characterized the material by size and using multiple reverse transcription droplet-digital PCR and qPCR methods. The agency is making the material free of charge through funding from the Coronavirus Aid, Relief, and Economic Security Act, in exchange for user feedback to help improve and further develop the material. 

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.